Home
Storia in 1 fonti
Merck Reports Topline Results From Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart - Merck
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an
Raccontata da
benzinga.com
Timeline cronologica
- ·
Merck Reports Topline Results From Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart - Merck
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2)…
- ·
Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy - Merck & Co (NYSE:MRK)
Merck reported positive Phase 3 data for tulisokibart in ulcerative colitis, meeting primary and key secondary endpoints.